Literature DB >> 8232727

Interaction of tacrine and velnacrine with neocortical synaptosomal membranes: relevance to Alzheimer's disease.

D A Butterfield1, K Hensley, N Hall, S Umhauer, J Carney.   

Abstract

The acridine-based, potential Alzheimer's disease therapeutic agents, tacrine and velnacrine, were incubated with rat or gerbil neocortical synaptosomal membranes. Electron paramagnetic resonance employing a protein-specific spin label was used to monitor this interaction. Analogous to their effects in erythrocyte membranes [Butterfield and Rangachari (1992) Biochem. Biophys. Res. Commun. 185: 596-603], in the present studies both agents decreased segmental motion of spin labeled synaptosomal membrane proteins, consistent with increased cytoskeletal protein-protein interactions (0.001 < P < 0.005), and tacrine was more potent than velnacrine. These results are discussed with possible relevance to molecular actions of the agents and molecular alterations in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8232727     DOI: 10.1007/bf00966758

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  31 in total

Review 1.  The spectrin-actin junction of erythrocyte membrane skeletons.

Authors:  V Bennett
Journal:  Biochim Biophys Acta       Date:  1989-01-18

2.  9-Amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease, inhibits acetylcholinesterase activity and slow outward K+ current.

Authors:  B Drukarch; K S Kits; E G Van der Meer; J C Lodder; J C Stoof
Journal:  Eur J Pharmacol       Date:  1987-09-02       Impact factor: 4.432

3.  Tetrahydroaminoacridine blocks voltage-dependent ion channels in hippocampal neurons.

Authors:  M A Rogawski
Journal:  Eur J Pharmacol       Date:  1987-10-06       Impact factor: 4.432

4.  9-Amino-1,2,3,4-tetrahydroacridine (THA) is a potent blocker of cardiac potassium channels.

Authors:  W Osterrieder
Journal:  Br J Pharmacol       Date:  1987-11       Impact factor: 8.739

5.  Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.

Authors:  I Grundke-Iqbal; K Iqbal; Y C Tung; M Quinlan; H M Wisniewski; L I Binder
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

6.  Spin label and biochemical studies of erythrocyte membranes in Alzheimer's disease.

Authors:  W R Markesbery; P K Leung; D A Butterfield
Journal:  J Neurol Sci       Date:  1980-03       Impact factor: 3.181

7.  Membrane processes associated with the osmotic-pulse incorporation of inositol hexaphosphate.

Authors:  J W Wyse; R S Franco; R Barker; M A Yacko; D A Butterfield
Journal:  Biochim Biophys Acta       Date:  1990-02-16

8.  Spin-labelling studies of the interaction of 9-amino-1,2,3,4-tetrahydroacridine (THA), a proposed drug for the treatment of Alzheimer's disease, with erythrocyte membranes.

Authors:  D A Butterfield; D A Palmieri
Journal:  Free Radic Res Commun       Date:  1990

Review 9.  Spectroscopic methods in degenerative neurological diseases.

Authors:  D A Butterfield
Journal:  CRC Crit Rev Clin Neurobiol       Date:  1986

10.  Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type.

Authors:  W K Summers; L V Majovski; G M Marsh; K Tachiki; A Kling
Journal:  N Engl J Med       Date:  1986-11-13       Impact factor: 91.245

View more
  4 in total

1.  Structural alterations in synaptosomal membrane-associated proteins and lipids by transient middle cerebral artery occlusion in the cat.

Authors:  N C Hall; R J Dempsey; J M Carney; D L Donaldson; D A Butterfield
Journal:  Neurochem Res       Date:  1995-10       Impact factor: 3.996

2.  Velnacrine in Alzheimer's Disease : An Initial Appraisal of its Clinical Potential.

Authors:  K L Goa; A Fitton
Journal:  CNS Drugs       Date:  1994-03       Impact factor: 5.749

3.  NO synthase and xanthine oxidase activities of rabbit brain synaptosomes: peroxynitrite formation as a causative factor of neurotoxicity.

Authors:  G Deliconstantinos; V Villiotou
Journal:  Neurochem Res       Date:  1996-01       Impact factor: 3.996

Review 4.  Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease.

Authors:  A J Wagstaff; D McTavish
Journal:  Drugs Aging       Date:  1994-06       Impact factor: 3.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.